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The periosteum is a highly vascularised, collagen-rich tissue that plays a crucial role in directing bone 
repair. This is orchestrated primarily by its resident progenitor cell population. Indeed, preservation of 
periosteum integrity is critical for bone healing. Cells extracted from the periosteum retain their 
osteochondrogenic properties and as such are a promising basis for tissue engineering strategies for the 
repair of bone defects.  However, the culture expansion conditions, and the way in which the cells are 
reintroduced to the defect site are critical aspects of successful translation. Indeed, expansion in human 
serum and implantation on biomimetic materials has previously been shown to improve in vivo bone 
formation. As such, this study aimed to develop a protocol to allow for the expansion of human 
periosteum derived cells (hPDCs) in a biomimetic periosteal-like environment. The expansion 
conditions were defined through the investigation of the bioactive cues involved in augmenting hPDC 
proliferative and multipotency characteristics, based on transcriptomic analysis of cells cultured in 
human serum. Master regulators of transcriptional networks were identified and an optimised periosteal 
derived-growth factor cocktail (PD-GFC; containing β-Estradiol, FGF2, TNFα, TGFβ, IGF-1 and 
PDGF-BB) was generated. Expansion of hPDCs in PD-GFC resulted in serum mimicry with regards to 
the cell morphology, proliferative capacity and chondrogenic differentiation. When incorporated into a 
3D collagen-type-1 matrix and cultured in PD-GFC, the hPDCs migrated to the surface that represented 
the matrix topography of the periosteum cambium layer.  Furthermore, gene expression analysis 
revealed a downregulated Wnt and TGFβ signature and an upregulation of CREB, which may indicate 
the hPDCs are recreating their progenitor cell signature. This study highlights the first stage in the 
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The periosteum is a highly vascularised connective tissue that covers bone. It is composed of two layers; 
an inner cambium layer that contains a skeletal stem cell population and an outer fibrous layer composed 
of fibroblasts embedded within a collagen type-1 matrix (1)(2)(3). Collagen fibres located in the 
periosteum are relatively small and compact compared to collagen bundles found in the skin (3). The 
periosteum stem cell population located in the cambium layer acts as a major participant in bone 
development and fracture healing (4)(5). This population of multipotent cells are capable of self-
renewing and differentiating into osteogenic and chondrogenic lineages, which is partly dependent on 
the mechanical stabilisation of the fracture (4)(6). During endochondral ossification, for non-stabilised 
fracture repair, the periosteum contributes up to 90% of the chondrogenic cells required for the early 
cartilaginous callus (7).  
 
Bone has an extraordinary capacity for repair, however, repair fails when the defect reaches a critical 
size and/or becomes a non-union (8). These bone defects are typically in compromised conditions such 
as tumours, infection, major trauma or congenital malformation resulting in significant disruption of 
the periosteum layer (9). Various surgical procedures have been implemented to overcome failed 
healing including the use of autologous bone, which is the current gold standard. Additionally, 
generation of pseudo-periosteum using the masquelet membrane technique and periosteum grafts have 
shown potential for bone repair (10). Despite surgical advances, there is an unmet medical need for an 
‘off the shelf’ regenerative solution for large bone defects. This would overcome many of the caveats 
associated with surgery, including donor site morbidity, risk of infection and discomfort (4). To 
overcome these issues, regenerative medicine aims to repair damaged tissue using cell-based therapies.  
 
Periosteum derived cells (PDCs) are a promising cell source for bone repair, predominantly due to their 
intrinsic bone forming capacity (11)(12). Indeed, this cell population displays multipotent 
characteristics at single cell level and the ability to form a bone ossicle with haematopoietic 
compartment in vivo (13)(14). However, cell potency is lost during expansion over long periods of time, 
hence currently there is a limited window to apply these cells to clinical strategies (15). This is similar 
to other adult stem cell populations and as such there has been a defined effort to enhance the 
proliferative and differentiation capacity through optimisation of culture conditions. Currently, human 
mesenchymal stromal cells (hMSCs) are generally expanded in conventional culture media using foetal 
bovine serum (FBS), which provides bioactive molecules such as growth factors, hormones and proteins 
necessary for cell growth and function (15). However, a myriad of disadvantages and limitations are 
associated with its use. Indeed, it is an ill-defined supplement and is inconsistent with regards to the 
quality and quantity of bioactive compounds present thus resulting in lot-to-lot variability (16)(17). 
Additionally, the use of a xenogenic serum could result in possible immune-mediated rejection if used 
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for clinical translation of cell therapies (18). Furthermore, ethical concerns associated with the 
harvesting of FBS from foetal calves presents another significant challenge to its use (19).  
 
Various serum-free and xeno-free media have been developed in an attempt to negate the potential 
variability and safety concerns associated with the use of animal serum in clinical applications (20). 
Indeed, we have reported the beneficial effect of human allogeneic serum (hAS) on the in vitro 
differentiation and expansion of human PDCs (hPDCs). These findings were translated successfully in 
vivo where cells expanded in hAS outperformed FBS expanded cells in bone forming capacity, thus 
demonstrating culture memory from in vitro expansion (11). Interestingly, platelet lysate has also been 
shown to increase hPDC bone forming capacity (21). Nevertheless, the use of hAS for clinical 
applications would require extensive screening and a well-characterised pool of donors, which could 
prove problematic in a clinical setting. Therefore, it is attractive to develop alternative methods of 
incorporating the necessary factors required to maintain the proliferative and progenitor-like 
characteristics of hPDCs. Furthermore, an appropriate scaffold that replicates the periosteum and allows 
the creation of a suitable delivery device is required for clinical translation. 
 
Herein a protocol for the expansion of hPDCs in a biomimetic periosteal-like environment to facilitate 
delivery to a bone defect is proposed. The expansion conditions were defined through the transcriptomic 
analysis of cells cultured in hAS. Gene network analysis was utilised for the identification of the key 
master regulators activated by hAS cultured conditions. Through the identification and careful selection 
of these growth factors, we were able to achieve serum mimicry with regards to cell morphology, 
proliferative capacity and chondrogenic differentiation. When cells were incorporated into a 3D 
collagen type-1 rich matrix, the periosteal-derived growth factor cocktail (PD-GFC) caused the hPDCs 
to migrate to the surface representing the matrix topography of the periosteum cambium layer.  
Furthermore, gene expression analysis revealed downregulated Wnt and TGFβ with upregulated CREB 
signalling, which may indicate the hPDCs are recreating their progenitor cell signature. The successful 
development of this cell-specific cocktail is the first step in developing a periosteum-like environment 
that mimics the biology of the periosteum.  
 
Materials and Methods 
Human periosteum-derived cell cultures 
hPDCs were isolated from biopsies obtained from patients undergoing orthopaedic surgery as described 
elsewhere (14)(13). Human Medical Research (KU Leuven) approved all procedures, and the patient 
informed consent forms were obtained. Subsequently, hPDCs from a pool of six different donors (Age 
= 14.9  2.1 years; Male:Female = 4:2) were expanded in growth medium (GM) consisting of high-
glucose Dulbecco's Modified Eagle’s Medium (DMEM, Invitrogen, Paisley, UK) supplemented with 
10% batch-tested foetal bovine serum (FBS) and antibiotics-antimycotic solution (100 units/ml 
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penicillin, 100 μg/ml streptomycin and 0.25 μg/ml amphotericin B; Invitrogen, Paisley, UK) to passage 
5. All experiments described herein were performed in pooled hPDCs at passage 6. We have previously 
published the CD marker profile (CD73+, CD90+ and CD105+), tri-linage differentiation capacity 
(osteogenic, chondrogenic, adipogenic) and in vivo bone forming capacity (bone ossicle with marrow) 
of this donor pooled population (13)(11).  
 
Selection of growth factors by RNAseq 
We have previously tested the three hAS serum pools (minimum of 15 donors) used herein, with two 
different hPDC cell pools and observed very similar growth characteristics with each combination. This 
data is reported in Roberts et al (2014). To analyse the effects of the culture systems on the hPDCs, 
RNA sequencing (RNAseq) was performed on the aforementioned hPDC pool at sub-confluence (initial 
seeding density 1000 cells/cm2) following culture for 6 days in hAS serum (n=3; donor pooled) or FBS 
(n=3; different Gibco batch). RNA was extracted using the Illumina TruSeq Standard Total RNA 
Sample Prep Kit (Illumina, US). RNA integrity was validated using a BioAnalyzer (Agilent). 
 
RNAseq was performed at the Nucleomics Core (KU Leuven; Belgium). Libraries were generated from 
2 μg RNA using the TruSeq library prep kit (Illumina, San Diego) as per the manufacturer’s 
recommendations. Sequencing of all samples was carried out on the HiSeq2000 (Illumina), with read 
lengths of 50 base pairs. Between 25-39.3 million reads were sequenced for each sample. Distributions 
of the average read quality was calculated using the ShortRead 1.18.0 package from Bioconductor 
(http://www.bioconductor.org). Base calling accuracy, measured by the Phred quality score, was 
measured in all samples, with values of ≥30.  
Pre-processed reads were aligned with the reference genome of Homo sapiens (GRCh37.73) using 
Tophat v2.0.8b. Quality filtering to remove reads from the alignment that were non-primary mappings 
or had a mapping quality ≤ 20 was performed with SAMtools 0.1.19. The number of mapped reads 
varied between 17.7 and 28.3 million reads per sample. Subsequently, Cufflinks v2.1.1 was used to 
extract unique transcript-related features. A list of gene level coordinates was constructed by merging 
the exon chains of transcripts that belong to the same gene using mergeBed from the Bedtools v2.17.0 
toolkit. The number of exons and number of transcripts was subsequently computed for each gene. 
Genes where reads could be attributed to more than one gene (ambiguous) or could not be attributed to 
any gene (no feature) or which all samples have less than 1 counts-per-million (absent) were removed. 
This left 15,518 identified genes. GC-content was corrected in each sample using full quantile 
normalization on bins of GC-content with the EDASeq package from Bioconductor. Between-sample 
normalization (sample-specific variation due to the library size and RNA composition) were corrected 
for using full quantile normalization with the EDASeq package from Bioconductor. A Relative Log 
Expression plot using log2-scale normalized counts for each gene as expression level was constructed 
and resultant values of close to 0 indicated the normalization was successful. For each gene, the 
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expression levels of both conditions were estimated from the raw counts with the DESeq 1.14.0 package 
of Bioconductor and tested for differential expression based on a model using the negative binomial 
distribution. To select genes the corrected p-value was set at < 0.05 which resulted in 1331 differentially 
regulated genes (log2 ratio ≤ −1 or log2 ratio ≥ 1). 
 
The dataset was validated using quantitative Polymerase Chain Reaction (qPCR; described below). 
Differentially regulated genes were selected based on fold change ratios from the RNAseq datasets 
between cells cultured in hAS compared to FBS. The genes selected for data validation demonstrated a 
high up/down regulated expression (fold change >20), moderate change (fold change 10-20) and 
minimal up/down regulation (fold change <10) (gene panel detailed in supplementary Figure 1). The 
genes that were significantly differentially expressed between hAS and FBS were initially interrogated 
through the online platform DAVID (Database for Annotation, Visualization and integrated Discovery, 
http://david.abcc.nciforf.gov/) to determine the prominent biological processes involved in each of 
these culture conditions.  The data was further analysed using Ingenuity® Pathway Analysis (IPA®) 
(Qiagen, Netherlands) to identify activated networks and up-stream regulators controlling the divergent 
biology observed between hAS and FBS. All genes demonstrating a fold change >2 with respect to 
expression in hAS compared to FBS with a p-value <0.05 were extracted from the RNAseq data for 
analysis with IPA. Associated genomic relationships were generated including regulators indirectly 
connected to the primary targets observed, to help identify the upstream regulators.  Factors were 
selected according to their relationships with ten gene networks. Factors identified as significant 
upstream regulators were mapped onto the gene networks to interrogate their function in respect to each 
of the identified processes. A literature search was performed to determine any precedent for each factor 




Upstream regulators identified via IPA were assessed in vitro for their potential role in controlling 
hPDC gene expression, proliferation and metabolic activity. The selected factors (Vascular Endothelial 
Growth Factor  (VEGF; 10 ng/mL, Peprotech, UK), Dexamethasone (1x10-8 M, Sigma), Wnt3A (10 
ng/mL, R&D Systems), 17-β Estradiol (1x10-9 M, Sigma), Fibroblast growth factor-2 (FGF2; 10 ng/mL, 
ThermoFisher), Tumour Necrosis Factor α (TNFα; 5 ng/mL, Peprotech), Transforming Growth Factor 
(TGFβ; 10 ng/mL, Peprotech), Insulin Growth Factor-1 (IGF-1; 20 ng/mL, Peprotech) and Platelet 
Derived Growth Factor (PDGF-BB; 10 ng/mL, Peprotech) were applied in a ‘leave-one-factor-out’ 
strategy to identify the key regulators involved in stimulating the cells’ proliferation and differentiation 
in vitro. hPDCs were seeded on a 24 well plate at a density of 1000 cells/cm2 and cultured for seven 
days in the varying factor conditions supplemented with 1% FBS (concentration that when in 
combination with additional defined serum-free replacements the culture becomes notably defined; 
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(22)) in phenol red free, high glucose DMEM (Invitrogen through ThermoFisher Scientific, UK). 
Factors critical to analysed cell responses were combined to create PD-GFC. 
 
Analysis of in vitro cell response 
To assess metabolic changes the cells were also treated with PrestoBlue® Cell Viability Reagent 
(Thermo Fisher Scientific) following manufacturer’s instructions. This Resazurin-based assay induces 
changes in absorbance at 600 nm which were recorded using a Tecan Infinite® 200 PRO plate reader. 
Double-stranded DNA (dsDNA) quantification was carried out using the Qubit® dsDNA High 
Sensitivity Assay Kit (Thermo Fisher Scientific) following manufacturer’s instructions. Briefly, cell 
monolayers were lysed in RLT buffer (Qiagen) plus 10 μl/ml β-mercaptoethanol (Sigma Aldrich) (23). 
The lysate was diluted 1/10 in nuclease-free water (Sigma Aldrich). Readings were obtained using the 
Qubit™ 3.0 fluorometer and were calculated as total dsDNA [ng/μl]. Cell spreading was analysed by 
culturing cells for seven days at a cell density of 1000 cells/cm2, which were subsequently fixed with 
10% neutral buffered formalin (NBF) (Sigma, UK). Actin cytoskeleton was visualised through staining 
with phalloidin and nuclei counterstained with DAPI. Cell spreading was calculated via a Width: Length 
ratio measured digitally using ImageJ (National Institute of Health).  
 
Quantitative PCR 
Total RNA was isolated using the RNeasy kit (Qiagen, Germany) following manufacturer’s 
instructions. RNA was quantified using a NanoDrop spectrophotometer measuring at 260/280 nm, and 
1 µg RNA/sample was reverse transcribed using the High Capacity cDNA Reverse Transcriptase Kit 
(Thermo Fisher Scientific, Paisley, UK) with the program: 25°C for 10 min, 37°C for 120 min, 85°C 
for 5 min, and infinite hold at 4°C. Transcribed cDNA was assessed via the CFX96 Touch™ Real-Time 
PCR Detection System (40 cycles) using the iTaq Universal SYBR Green Supermix (Bio-Rad, 
Hertfordshire, UK). Primers were designed using Primer3 (listed in supplementary Table 1) and were 
designed to span an intron to isolate RNA specific amplification. Relative differences in expression 
were calculated using 2-∆∆Ct (24) normalised to HPRT expression.  
 
Analysis of hPDC growth kinetics 
The effect of PD-GFC on hPDC characteristics was assessed by expanding the cells in either PD-GFC 
medium or conventional GM. Cells were initially grown in conventional GM containing 10% or 1% 
FBS until confluency was reached and further subcultured in either GM (containing either 1% FBS or 
10% FBS) or PD-GFC medium over 4 passages (n= 3). Cumulative population doubling was calculated 
using the following equation: PDL = 3.32 (log Xe – log Xb) + S; where Xb is the cell number at the 
beginning of the culture, Xe is the cell number at the end of the culture and S is the population doublings 
at the start of the culture.  
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Analysis of hPDC differentiation  
Previously expanded cells (in either 10% FBS or PD-GFC) were subcultured at 70% confluency and 
then assessed for their differentiation capacity. Osteogenic differentiation was assessed using a defined 
osteogenic growth factor cocktail (25) on hPDCs passaged twice in either GM or PD-GFC- seeded at a 
density of 3000 cells/cm2 in their initial growth mediums for 24hrs. The media was replaced with 
conventional growth medium supplemented with Ascorbate-2-phosphate (57 μM, Sigma), TGF-β1 (10 
ng/mL, Peprotech), Epidermal Growth Factor (EGF; 20 ng/mL, Invitrogen), Interleukin-6 (IL-6; 10 
ng/mL, Peprotech), Calcium ions (3 mM) and Phosphate ions (2 mM). The cells were differentiated for 
a period of 7 days with media changed every 48 hrs. Differentiation was assessed through staining with 
alizarin red solution (pH 4.2). Quantification of calcium mineral deposits was performed by dissolving 
the incorporated dye with 10% cetylpyridinium chloride (in deionised water) for 60 minutes at room 
temperature. Absorbance was measured spectrophotometrically at 570 nm.  
Chondrogenic differentiation was assessed on hPDCs expanded over 3 passages in either GM or PD-
GFC and further seeded in high-density micromasses at a cell density of 5,000 cells/µL. Cells were 
allowed to adhere before culturing in chondrogenic medium consisting of low glucose DMEM 
(Invitrogen), 1x Insulin-transferrin-selenium supplement (Corning, UK),  Dexamethasone (100 nM, 
Sigma), Y27632 (10 µM, Axon, UK), ascorbic acid (50 µg/mL, Sigma), proline (40 µg/mL, Sigma) 
and TGF-β1 (10 ng/mL, Peprotech) for 7 days. Differentiation was evaluated by staining with Alcian 
Blue (Sigma) (pH 2.0) overnight at room temperature. Quantification of proteoglycans was carried out 
by extracting the Alcian blue dye from the micromass using 6M guanidine hydrochloride and measuring 
the absorbance at 620 nm.  
 
Adipogenic differentiation was assessed following hPDC culture over two passages in either GM or 
PD-GFC at a cell density of 30,000 cells/well in a 48 well plate for a period of 21 days. The cells were 
seeded in growth medium until the cells reached confluency after 48hrs. Once confluency was reached 
the media was substituted with adipogenic differentiation media containing 10% FBS, Insulin (1 
µg/mL, Sigma), Dexamethasone (0.1 µM, Sigma), Isobutylmethylxanthine (IBMX; 4.5 µM, Sigma) 
and indomethacin (125 µM, Sigma). Media was changed every 2 days. Production of fat droplets was 
assessed using oil red O stain and lipid droplet area quantified using ImageJ (National Institute of 
Health). Gene expression analysis was performed on stem, osteogenic, chondrogenic and adipogenic 
markers and qPCR conducted as previously described. 
 
Formation of collagen-type 1-hPDC seeded scaffold 
hPDCs were expanded until 80% confluency was reached. Rat tail collagen type-1 (First Link, UK) 
gels were prepared according to the RAFT protocol. A collagen master-mix was prepared containing 
10% 10x DMEM, 80% Rat tail collagen type-1 (2.05 mg/ml in 0.6% acetic acid) and a 10% neutralising 
agent composed of 10 M NaOH and Hepes buffer (ThermoFisher Scientific, UK) (26). The collagen 
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solution was set on ice for a minimum of 30 minutes to allow for the movement of air bubbles out of 
the solution. The cells were prepared and incorporated into the collagen master mix to produce collagen 
scaffolds with a density of 100,000 cells per gel. A volume of 1.3 mL of the collagen master mix was 
dispensed into 24 well plates. The gels were allowed to gelate at 37℃ for 15 minutes allowing for 
fibrillogenesis of the collagen hydrogel, comprised of a network of intertwined fibrils with no inherent 
orientation consisting of a large excess fluid to collagen ratio (27). To achieve a denser (10%) collagen 
matrix, the gelated constructs underwent plastic compression using a hydrophilic RAFT absorber, 
following the Lonza ‘RAFT 3D Cell Culture’ protocol. Briefly, the absorber was placed on top of the 
gel for 15 minutes to expel the fluid content through the main (basal) fluid leaving surface of the gel. 
This resulted in a ~50 fold increase in collagen density (28).  Following plastic compression, the 
absorber was removed and 1 mL of GM was added to the well. After 24hrs, the media was substituted 
with either 10% FBS containing medium or the PD-GFC and cultures were allowed to incubate for a 
period of 14 days. The collagen gels were subjected to histological analysis: paraffin embedded sections 
were stained for cell cytoplasm and nuclei with haematoxylin and eosin, respectively.  
 
RT2 Profiler PCR Array of Human stem cell signalling  
To further interrogate the signalling mechanisms involved when the hPDCs were cultured in either FBS 
or PD-GFC in 3D, an RT2 Profiler PCR array (Qiagen) specific for stem cell-associated signalling 
pathways was utilised. The array profiles 84 key genes representative of six different signal transduction 
pathways associated with identification, growth and differentiation of stem cells. The hPDCs were 
embedded within the collagen type-1 matrix as detailed above and subsequently cultured in either FBS 
containing growth media or PD-GFC for a period of 14 days. Samples were lysed using TRI reagent 
and RNA isolated using the chloroform phase separation technique and subsequently processed using 
the RNeasy Kit (Qiagen) according to manufacturer’s instructions (29). Single strand cDNA was 
transcribed using 1 µg total RNA, synthesised using the RT2 first strand kit (Qiagen). Real-time PCR 
was performed using the RT2 profiler array system according to manufacturer’s instructions in 
combination with RT2 SYBR Green qPCR Mastermix (Qiagen) in a Biorad CFX96 PCR system 
(Biorad). Data Analysis was conducted using a web-based RT2 PCR Profiler PCR array data analysis 
software (Qiagen). Genes were identified as up or downregulated with a fold change cut off of 2, with 
a corresponding p-value <0.05. P-values calculated based on student’s t-test of the replicate 2-∆∆Ct values 
for each gene in the FBS group and corresponding PD-GFC experimental group.  
 
Stiffness of native periosteum and collagen-type 1 scaffold 
Native bovine periosteum and seeded 10% collagen type-1 cell laden scaffolds (following 14 days 
culture in PD-GFC; n=3) were washed with PBS and embedded in optimal cutting temperature 
compound (OCT). Embedded samples were cryosectioned into 10 m sections, transferred onto glass 
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slides and stored at room temperature. Atomic Force Microscopy (AFM) was performed on these 
samples using a JPK Nanowizard 1 AFM (JPK Instruments Ltd, Germany) with RFESPA-75 cantilever 
(k=0.3N/m). 100 measurements were performed within a 10 m2 surface area in 6 locations of each 
tested region within the tissue/scaffold.  
 
Statistical Analysis 
Data are expressed as mean ± standard error of the mean (SEM). Statistical significance was determined 
using one-way ANOVA with Fisher’s LSD post hoc corrections applied or student’s t-test. Statistical 
significance is indicated on all graphs as follows: *p<0.05, **p<0.01, ***p<0.001 (n=3). All statistical 
analysis was performed using GraphPad Prism version 6.0f for windows (GraphPad Prism Software, 




Identifying the regulators associated with hAS induced hPDC potency 
hPDCs cultured in 10% FBS and 10% hAS for 6 days were subjected to RNASeq to analyse the 
transcriptomic profile of the cells in each condition. Prior to conducting further analysis with the data, 
the RNA Seq dataset was validated by qPCR profiling of the following markers: Human Transgelin 3 
(TAGLN3), BCL2 related protein A1 (BCL2A1), Sulfotransferase family 1B member 1 (SULT1B1), 
C-X-C motif chemokine ligand 22 (CXCL2), PDK1 family protein kinase (PDKA4), Matrix 
metallopeptidase 1 (MMP1), Semaphorin 3A (SEMA3A), Angiopoietin-like 1 (ANGPTL1), Platelet 
derived growth factor subunit A (PDGFA), Noggin (NOG), Alpha kinase 2 (ALPK2), Cartilage 
intermediate layer protein 2 (CILP2), Insulin like growth factor 1(IGF-1), and Fibroblast growth factor 
9 (FGF9). Relative expression values obtained using qPCR were comparable to those measured by 
RNA Seq with no significant differences observed (Supplementary Figure 1).    
 
To determine the specific factors involved in regulating the cell’s characteristics when cultured in hAS 
relative to FBS, IPA software generated a list of all upstream regulators (factors that are predicted to 
have a downstream effect on other molecules) associated with multiple targets within each identified 
pathway (Supplementary Table 2). The upstream regulators were arranged with respect to their overlap 
p-value (Right tail Fisher’s exact test) which measures whether a statistically significant overlap is 
present between the experimental data set and the genes regulated by the upstream transcriptional 
regulators. The regulators with a significant overlap are predicted to have a significant effect within the 
culture system. The top 20 upstream regulators were then recorded as potential factors responsible for 
the characteristics observed in cells cultured in hAS. 
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An additional methodology incorporated in the identification of key factors was the assessment of gene 
networks (Supplementary Table 3), whereby hub genes with direct and indirect gene/protein 
interactions were identified. To validate the top 20 upstream regulators, each was mapped to the 
network, and genes that identified as both upstream regulators and hub genes within these networks 
were recorded. Two networks associated with embryonic, organismal, tissue development and cellular 
movement, haematological system development and function, immune cell trafficking were identified 
with the most recorded differential genes (Figure 1).  
 
To further assess the validity of the selected factors a literature search was carried out on each to identify 
any known involvement in inducing cellular proliferation, bone formation or stemness (Supplementary 
Table 4). This resulted in 9 factors being selected for further analysis, including VEGF, 












Figure 1: Gene networks associated with hAS culture of hPDCs A) Predicted upstream regulators integrated 
within a network involving Embryonic Development, Organismal Development, and Tissue Development. B) 
Predicted upstream regulators integrated within a network involving Cellular Movement, Hematological System 
Development and Function, and Immune Cell Trafficking. Upstream regulators selected for the PD-GFC are 
represented on both networks. Red indicates up-regulation whilst green indicates down-regulation. Grey 
indicates genes that are significantly changed in expression by less than 2-fold and white represents genes not 
significantly altered in the study but have been incorporated into the network through relationships with other 
molecules. Yellow indicates potential upstream regulators. Networks created in Ingenuity Pathway Analysis (IPA; 
Qiagen).  
 
Assessing the effects of the selected factors on hPDC culture dynamics 
The effect of each selected factor on hPDC biology was assessed using a “leave-one-factor-out” 
strategy, which was aimed at identifying the factors that induce cellular proliferation and a gene 
expression profile with enhanced stem and osteochondrogenic gene expression (Figure 2). hPDCs were 
cultured in the various conditions for a period of 7 days. The condition containing all factors was used 
A B
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as a reference to evaluate the impact of each individual factor on proliferation and cellular metabolism 
(Figure 2B), and the expression of stem (Nestin (30) and Prx1 (31) based on previously published data 
indicating their relevance in the identification of cells from mesenchymal origin with apparent 
plasticity), early osteogenic and chondrogenic gene markers (Figure 2A). A positive regulation upon 
elimination of a factor compared to the reference indicated that this factor had a negative effect on the 
measurement. In this regard, we identified FGF2 as a strong inducer of proliferation (2.2 fold decrease 
in DNA content upon its elimination, p<0.001), metabolism (1.25 fold decrease in metabolic activity) 
and stemness (NESTIN: 1.2 fold decrease; PRX1: 1.7 fold decrease, p<0.05), however, minimal effects 
were observed with regards to early osteogenic (RUNX2: 1.4 fold increase, ALP: 1.2 fold increase) and 
chondrogenic (SOX9: 1.2 fold decrease and COL2A1: 2.2 fold increase, p<0.001) markers. TGFβ on 
the other hand had a minimal effect when considering metabolism (1.1-fold increase, p<0.05), however 
its removal decreased the expression of NESTIN (1.9-fold decrease, p<0.01), RUNX2 (2.5-fold 
decrease, p<0.01), ALP (6-fold decrease, p<0.001) and COL2A1 (10-fold decrease, p<0.05). 
 
TNF and βEstradiol were the only molecules that when removed induced a significant increase in the 
committed osteoblast marker ALP. As the primary goal of this study was to define culture conditions 
that allow the expansion of hPDCs in the absence of differentiation, both were retained in the culture 
conditions. In the case of IGF-1 and PDGF-BB, their removal caused minimal change in any tested 
parameter, however, removal caused the appearance of a heterogeneous culture and/or stress fibres 
within the cells and as such both were retained (Supplementary Figure 2).   
 
Eliminating dexamethasone resulted in a significant increase of all tested gene markers (NESTIN: 1.8-
fold, p<0.001; PRX1: 1.4-fold, p<0.001; RUNX2: 1.5-fold, p<0.001; SOX9: 1.86-fold, p<0.001; 
COL2A1: 0.8-fold, p<0.01) with the exception of ALP (5-fold decrease, p<0.001). With this reasoning, 
dexamethasone was eliminated from the growth factor cocktail. Additionally, eliminating WNT3A 
from the study significantly increased cellular proliferation (0.3-fold increase, p<0.05) with no 
significant effect on cellular metabolism and all tested gene markers and was thus eliminated from the 
study. Lastly, eliminating VEGF caused a significant increase in proliferation (0.4-fold change, p<0.01) 
and cellular metabolism (0.4-fold change, p<0.01), with no significant effect on tested gene markers, 
and was thus eliminated from the study.  
 
Using this methodology, a refined cocktail of factors was generated that included βEstradiol, FGF2, 
TNFα, TGFβ, IGF-1 and PDGF-BB. This was termed periosteum-derived growth factor cocktail (PD-
GFC). The morphology of cells cultured in hAS and PD-GFC was similar (Figure 2C) indicating 
potential equivalence of the culture conditions based on cell phenotype.  
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Figure 2: Leave-one-factor-out strategy to identify factors important for hPDC potency A) Expression of 
stem markers; NESTIN and PRX1, osteogenic markers; RUNX2 and ALP, and chondrogenic markers; COL2A1 
and SOX9. Horizontal line indicates expression levels relative to the ‘all factors’ condition. B) Quantification of 
cellular DNA to assess proliferation and percentage increase in metabolic activity was assessed. Growth factors 
eliminated from the study are represented as grey bars. (Data are presented as the mean ±S.E.M, Statistical 
analysis performed using one-way ANOVA, uncorrected Fischer’s LSD; ***p<0.001; **p<0.01; *p<0.05; n=3). 
C) Representative fluorescence images illustrating nuclear DAPI staining and cytoskeleton staining of hPDCs 
cultured in All factors, hAS, and the refined PD-GFC. Note the similar morphology of hPDCs cultured in PD-










hPDCs cultured in PD-GFC display differences in cellular morphology and lineage commitment in 
vitro compared to 10% FBS 
To assess the efficacy of the PD-GFC for hPDC expansion, hPDCs were treated with the PD-GFC over 
multiple passages to observe its effect on the cell’s proliferation rate relative to 10% and 1% FBS. 
Culture of hPDCs in PD-GFC resulted in a significantly higher cumulative population doublings over 
time and per passage (after P8) compared to 10% FBS and 1% FBS (P<0.05) (Figure 3A and B). The 
cells remained proliferative after P10 and appeared morphologically normal. Data associated with a 
typical passage in each of the media formulations is shown in Supplementary Table 5. However, it 
cannot be categorically stated from these data that no senescent cells were present within the cultures. 
With regards to cell spreading, the ratio of the cells width to length was quantified when treated with 
1% FBS, 10%FBS and PD-GFC (Figure 3B). hPDCs cultured in PD-GFC resulted in a 3.1-fold lower 
ratio than when cultured in 10% FBS (p<0.001; Figure 3C), which follows the same trend as previously 
published for hAS-cultured cells (11). Furthermore, the expression of mesenchymal stem marker 
NESTIN was higher at each passage when cultured in PD-GFC compared to 10% FBS (1.9, p<0.01; 
3.3, p<0.001; 2.0, p<0.01; and 2.6-fold, p<0.001 higher at passage 7-10 respectively). In cells treated 
with the PD-GFC relative to 10% FBS, PRX1 displayed an increase in expression in PD-GFC treated 
cells at passage 7 (1.3- fold, ns), 8 (1.3-fold p<0.05), 9 (1.2-fold, ns) and passage 10 (2.0, p<0.001) 
when compared to 10% FBS (Figure 3D). The expression of the osteogenic transcription factor RUNX2 
was increased in the PD-GFC treated cells, with a significant increase observed at passages 8 (3.4-fold, 
p<0.001), 9 (1.8-fold, p<0.05) and 10 (5.0-fold, p<0.001). Interestingly, ALP expression was lower in 
PD-GFC treated cells and significantly lower at P8 (3.0-fold, p<0.01) and 10 (1.5- fold, p<0.01). With 
regards to chondrogenic markers, SOX9 displayed a lower expression profile at passages 7-10 in cells 
treated with PD-GFC though not significant. COL2A1 expression was however, significantly up 
regulated in PD-GFC treated cells at passage 7-10 (17.0 (p<0.01), 11.4 (p<0.001), 4.8 (p<0.05), 5.0 
(p<0.01)- fold, respectively) relative to 10% FBS.  
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Figure 3: Validation of PD-GFC as a defined media for hPDC culture. A) Population growth curves of hPDCs 
expanded in 1% FBS, 10%FBS and PD-GFC. B) Cumulative population doublings in all three media conditions at 
all tested passages 7-10 (P7-10). Significant differences observed in cells expanded in PD-GFC relative to FBS (*, 
PD-GFC relative to 10% FBS; #, PD-GFC relative to 1% FBS). C) Cell spreading of hPDCs in 1%FBS, 10%FBS and PD-
GFC. Data are presented as the mean ±S.E.M. Statistical analysis performed using one-way ANOVA, uncorrected 
Fischer’s LSD; T-test, Mann-Whitney test (***,###p<0.001; **,##p<0.01; *p<0.05; n=3). D) Representative 
fluorescence images illustrating cellular spreading of hPDCs cultured in 1% FBS, 10%FBS and PD-GFC for a period 
of 6 days (nuclear DAPI staining and cytoskeleton staining with Phalloidin; Scale= 50 m). E) Stem markers; 
NESTIN and PRX1, osteogenic markers; RUNX2 and ALP, and chondrogenic markers; COL2A1 and SOX9; 
expression measured using qPCR. (Data are presented as mean ±S.E.M, Statistical analysis performed using one-



























































































































































































































































































Expansion in PD-GFC maintains hPDC osteochondrogenic potential 
Following expansion of hPDCs through multiple passages (as mentioned above), a subset of cells were 
subjected to standard chondrogenic, osteogenic and adipogenic differentiation conditions. The data 
illustrated in Figure 4A is a representation of the chondrogenic differentiation assay. The micromass 
cultures treated with standard chondrogenic factors resulted in a 1.8-fold increase (p<0.05) in alcian 
blue stain, indicative of proteoglycan deposition in cells previously expanded in the PD-GFC relative 
to 10% FBS (Figure 4A). The early chondrogenic transcription factor SOX9 was significantly up 
regulated (2.3-fold, p<0.001) in the PD-GFC primed cells compared to 10% FBS cultured cells.  
 
Osteogenic differentiation was conducted for 7 days (Figure 4B), with no significant differences in 
calcium phosphate deposition illustrated by an alizarin red stain between the two expansion medias. A 
modest reduction in the expression of the osteogenic transcription factor RUNX2 (1.3-fold, p<0.01) was 
observed in PD-GFC cultured cells compared to 10% FBS.  
 
The cells were further subjected to an adipogenic differentiation assay for 21 days (Figure 4C). An oil 
red O stain was performed identifying the formation of fat droplets. Cells cultured in 10% FBS prior to 
the differentiation assay resulted in the formation of large fat droplets. However, cells cultured in PD-
GFC resulted in immature fat droplet formation after the 21-day period, further confirmed by a 23.4-
fold decrease in lipid droplets (Figure 4C). A 52.6-fold decrease in the adipogenic marker FABP4 was 
observed in PD-GFC expanded cells relative to 10% FBS.  
 
 
Figure 4: Defining the effect of PD-GFC on hPDC differentiation and potency A) Chondrogenic differentiation 
was conducted after hPDCs underwent 4 passages in either 10% FBS or PD-GFC. Micromasses were stained and 
quantified with Alcian blue at day 7, with SOX9 transcription factor analysed by qPCR (Scale bar =3 mm). hPDCs 
cultured in PD-GFC had a significantly higher glycosaminoglycan content compared to hPDCs cultured in 10% 
FBS and significant increases in SOX9 expression (p<0.01). B) After 2 passages, an osteogenic differentiation 
assay was conducted for 7 days, with no significant differences in calcium phosphate deposition illustrated by 
alizarin red stain, however, a significantly lower expression of osteogenic related transcription factors RUNX2 in 
PD-GFC cultured cells. C) After 2 passages, an adipogenic differentiation assay was performed and fat droplets 
analysed using Oil red O stain. Distinct fat droplets observed in cells cultured in 10% FBS with immature fat 
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droplets observed in PD-GFC cultured cells, with a lower gene expression of the adipogenic associated maker 
FABP4 compared to 10% FBS cultured cells. (Data are presented as the mean ± S.E.M, Statistical analysis 
performed using one-way ANOVA, uncorrected Fischer’s LSD; ***p<0.001; **p<0.01; *p<0.05; n=3, scale bar= 
10 µm).  
 
 
hPDCs encapsulated within a 3D Collagen type-1 matrix and cultured in PD-GFC display periosteum 
like characteristics  
hPDCs were embedded within a 3D collagen type-1 matrix. The aim of this study was to further 
recapitulate the in vivo periosteum microenvironment by incorporating the cell populations in optimised 
culture conditions in a relevant matrix. 100,000 cells were either seeded in a 2D monolayer or embedded 
within 10% (plastic compressed) 3D collagen type-1 matrix. After a 14-day culture, the constructs were 
paraffin embedded, sectioned and stained with haematoxylin and eosin to observe the collagen and cell 
distribution. Upon plastic compression of the collagen gels, a dense layer of collagen was visible on the 
fluid leaving surface (FLS) compared to the rest of scaffold (Figure 5B).  The 10% FBS cultured 
constructs had cells dispersed throughout the matrix. However, when cultured in PD-GFC, more hPDCs 
were visible within the construct with the majority of cells aligned along the FLS of the scaffold. 
Interestingly, this did not occur when using a lower cell density of 30,000 cells (Supplementary Figure 
3A). Intriguingly, the organisation of the cells mirrored that of native periosteum (Figure 5A). 
Furthermore, when comparing the gene expression profile of this biomimetic construct to cells cultured 
in standard conditions, an upregulation of genes associated with periosteal biology was observed with 
the exception of Prx1 (Supplementary Figure 3B). We hypothesised that this cell organisation was due 
to the biophysical properties of this region, and as such set out to analyse the morphology of the collagen 
fibrils and the matrix stiffness of both the native periosteum and hPDC laden collagen type 1 scaffold 
following 14 days culture in PD-GFC. As seen in Figure 5E, Atomic Force Microscopy (AFM) stiffness 
measurements of either side of the scaffold revealed no difference, unlike native periosteum where the 
fibrous layer was 1.47-fold stiffer than the cambium layer. Interestingly, the scaffold stiffness was in 
the same range as that observed with periosteum (Scaffold = 5.40-5.45 GPa, Periosteum = 4.55-6.69 
GPa).  With regards to collagen fibril morphology, collagen fibril structure and orientation was similar 
between the FLS and cambium layer, respectively. A similar fibril morphology was also observed 





Figure 5: Effect of PD-GFC on hPDCs cultured in a collagen matrix – creation of an engineered periosteum. 
hPDCs were cultured in either a 2D monolayer or a 3D environment containing 10% rat-tail collagen type 1 for a 
period of 7 and 14 days. The cells were exposed to either 10% FBS or PD-GFC in all aforementioned 
environments. A) H&E stain of bovine periosteum illustrating the cell dense-cambium layer and fibrous layer 
(scale bar: 50 µm). B) Collagen scaffolds cultured in either 10% FBS or PD-GFC at day 14. Cellular migration 
of hPDC visible towards the dense fluid leaving surface (FLS) in PD-GFC cultured scaffolds (scale bar: 50 µm). 
C) Images of collagen fibrils in PD-GFC cultured collagen type 1 scaffolds at the FLS and bottom surface of the 
scaffold (scale bar: 2µm). D) Images of collagen fibril orientation of a native periosteum within the cambium 
layer and fibrous region of the tissue. E) Stiffness measurements of native periosteum tissue and collagen type 1 
scaffold. The graphs illustrate the median stiffness from each specific region. F) Volcano plot of genes 
significantly up and down regulated in PD-GFC cultured hPDCs in a 3D construct relative to FBS cultured cells 
(p<0.05) with a fold change >2.  G) Gene network representing various signalling interactions between genes that 




























Identification of signal transduction factors associated with PD-GFC cultured hPDCs 
To further determine the underlying mechanisms involved in PD-GFC culturing of hPDCs in a 3D 
environment, cells were embedded in a 3D collagen type 1 matrix and cultured in either 10% FBS or 
PD-GFC for 14 days. RNA was extracted and changes in gene expression was observed using the 
human stem cell signalling array. Of the 84 genes examined, 9 genes were significantly upregulated in 
PD-GFC cultured cells relative to FBS and 17 genes were significantly downregulated in PD-GFC 
cultured cells relative to FBS with a 2-fold or more change in expression, illustrated in the volcano plot 
(Figure 5F). The data was further interrogated using IPA to define the likely gene network associated 
with the transcriptional profile. The gene network shown in Figure 5G represents genes from the PCR 
array that were either up (red) or downregulated (green) with additional genes that are likely to play a 
role also represented. It was noted that TGF superfamily (ACVR2B, ACVR1B, SMAD1 and SMAD4), 
Wnt signalling (FZD7, TCF and LEF1) and Hedgehog (GLI2, PTCHD2) were downregulated with an 
upregulation of CREB associated pathways (CREBBP and EP300).  
 
Discussion 
The identification of gene networks that are activated during stem cell expansion, whilst retaining 
potency, is an essential step in tissue engineering and regenerative medicine. Although generic defined 
culture conditions have been commercialised, many of these contain a proprietary formulation of 
growth factors and small molecules and as such delineating data generated using these media remains 
difficult. We have previously demonstrated the superiority of hAS over FBS in supporting hPDC 
expansion, osteochondral differentiation and in vivo bone tissue formation (11). However, the specific 
signals involved in this effect are largely unknown. Through the comparison of gene expression in 
hPDCs cultured in hAS and FBS we show that the in vitro molecular signature associated with hAS 
induced identity and potency can be used to develop defined culture conditions for hPDC culture.  
Furthermore, these culture conditions can be combined with high density collagen 3D matrices to 
promote periosteum-like tissue formation in vitro. Indeed, mimicking the periosteum microenvironment 
as a means of facilitating bone regeneration in vivo, is a credible method of introducing cells into bone 
defects that lack the key components to initiate the repair process.  
 
Serum contains over 1,000 different components, including proteins, lipids, carbohydrates, growth 
factors, enzymes and other constituents that are still undefined. The precise effect of serum is cell type 
specific, however, generally it regulates cell growth and phenotype. As previously stated, we have 
shown that serum from human sources outperforms those from bovine sources when culturing hPDCs, 
however the mechanism of this effect and factors that mediate it are largely unexplored. Indeed, 
although EGF, FGF-2, PDGF, VEGF and IGF-1 have been identified as key growth factors in human 
serum (32), whether all or only some confer hPDC identity and potency is unknown. Interestingly, 4 of 
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these factors are represented in the 9 factors identified from transcriptomic analysis of hAS cultured 
hPDCs (PDGF-BB, β-estradiol, WNT3A, IGF-1, TNFα, TGFβ, VEGF, FGF2 and Dexamethasone). 
Furthermore, each of these 9 factors have also been implemented in stem cell culture and increased 
potency. There is already a wealth of literature suggesting these factors are important in: 1. Delaying 
MSC senescence (Oestrogen and Dexamethasone) (33)(34)(33); 2. Improving proliferation (Oestrogen, 
Dexamethasone, PDGF, Wnt3a, VEGF, and FGF) (36)(37)(38)(39) and 3. Regulating osteo/chondro 
commitment (TNF, TGF, IGF) (40)(41)(42)(38). Involvement of each of the selected factors in stem 
cell/bone biology is summarised in Supplementary Table 4. Of course, the validity of each of these 
factors for increasing hPDC potency, and potential interactions, requires careful testing empirically.  
 
In an attempt to create a cocktail of growth factors that stimulate robust expansion of hPDCs with 
improved potency, a take-one-away methodology was used. It was predicted that when analysed with 
respect to cell proliferation and gene expression profile, a conclusion on the specific factor’s importance 
could be made.  For example, the inclusion of Wnt-3a in the initial growth factor list was predominantly 
a result of its significance as an upstream regulator in the transcriptomic analysis and previous studies 
indicating its role in bone metabolism and MSC proliferation. However, studies have reported 
contradictory results with regards to Wnt3a and osteocommitment, which appears to be dependent of 
cell type and stage of differentiation. Indeed, when considering adipose derived MSCs, Wnt3A 
increased the early marker ALP, but mature osteoblast markers were not increased (43). Conversely, a 
positive effect on multipotent characteristics and proliferative state has been suggested for bone marrow 
MSCs when FGF2 and Wnt3a care combined (44). Nevertheless, herein, eliminating Wnt-3a had a 
positive effect on cell proliferation but no effect on any stem or osteochondrogenic markers.  
 
The elimination of Dexamethasone resulted in a significant upregulation of all tested gene markers 
(with the exception of ALP) as well as enhancing cellular proliferation and metabolism. Due to its dose 
dependent mechanism, Dexamethasone has previously been reported to both promote and arrest 
osteogenic differentiation. Interestingly herein, Dexamethasone appeared to have a negative effect on 
hPDC biology. Indeed, we have previously reported that Dexamethasone overall has a negative effect 
on osteogenic differentiation, unless in combination with 10% FBS (45). Likewise, eliminating VEGF 
from culture resulted in minimal alteration in analysed markers, but did promote proliferation and 
metabolism relative to all factors. VEGF is known to promote osteogenic differentiation, however, a 
lack of effect when considering PDCs may represent a cell specific mechanistic difference. In summary, 
eliminating a combination of Wnt-3a, Dex and VEGF had minimal negative effect in the cell’s stem, 
osteogenic and chondrogenic markers relative to all other factors with the cell’s morphology resembling 
that of cells cultured in hAS. This allowed the formulation of the defined PD-GFC culture conditions. 
 
 21 
A significant difference was observed in the proliferation of cells cultured in PD-GFC relative to FBS, 
as previously reported with hAS (11). In addition, cell morphology and spreading of hPDCs cultured in 
PD-GFC mimicked that of cells cultured in hAS (11). Furthermore, hPDCs cultured in PD-GFC 
demonstrated significant increases in stem cell markers PRX1 and NESTIN over serial passages and an 
increase in the chondrocyte marker COL2A1 and osteogenic marker RUNX2. When expanded in PD-
GFC, the resultant cells had a greater propensity to deposit GAGs when differentiated towards 
chondrocytes, and a decrease in fat droplet content when differentiated towards adipocytes, compared 
to cells cultured in 10% FBS. Indeed, this mirrored the results with hAS, with the exception of CaP 
deposition where an increase was observed compared to FBS (46). However, hPDC optimised 
osteogenic differentiation conditions were used herein, which were not used in the earlier study. 
Interestingly, periostin (POSTN) has been proposed as a key regulator of the cell’s differentiation 
capacity (47). Indeed, culturing hPDCs in the PD-GFC caused a significant up regulation of POSTN 
(not shown) compared to FBS cultured cells, which may account in part for the enhanced differentiation 
capacity of the cells.   
 
In an attempt to further mimic the periosteum in vitro, the cells were incorporated within a collagen 
type-1 matrix. Interestingly, we observed a distinct migration of cells to the fluid leaving surface of the 
collagen scaffold by day 14 (illustrated on the bottom edge of the collagen scaffolds in Figure 5B) when 
culturing the cells in PD-GFC. This resembled the cell distribution seen in native periosteum where cell 
density is increased in the cambium layer of the periosteum (as illustrated in Figure 5A). A significant 
increase in expression (***, p<0.001) of the periosteum associated gene cathepsin K (CTSK) (data not 
shown), was seen in scaffolds cultured in PD-GFC relative to FBS by day 14. CTSK is a collagenase 
enzyme that has recently been shown to be expressed in a subpopulation of periosteal stem cells (6), 
however in this instance it may be aiding matrix remodelling, thus allowing cell movement.   In an 
attempt to define the cues relating to cell movement we assessed whether matrix stiffness was regulating 
migration. Interestingly, no difference was observed between the stiffness of the two surfaces of the 
scaffold, although they were in the same stiffness range as native periosteum. However, upon analysis 
of collagen orientation of both the scaffold and periosteum, a similar interwoven morphology was 
observed between the cambium layer and FLS of the scaffold. Additionally, a similar longitudinally 
oriented collagen fibre morphology was observed between the fibrous layer and bottom of the scaffold. 
As such, the matrix ultrastructure could be a potential cue in regulating the migration of cells to the 
various regions of the scaffold. Indeed, contact guidance and bidirectional migration along aligned 
collagen fibres is a known phenomenon in both wound healing and cancer biology (48). The increased 
population of hPDCs at the FLS when cultured in the PD-GFC suggests a synergistic effect of the dense 
interwoven collagen matrix as well as the presence of active cytokines and growth factors that may 
have encouraged the accumulation of PDCs. This pattern and localisation of cells in a collagen matrix 
is reminiscent of the cambium layer of the periosteum.  
 22 
 
When assessing the signalling transduction pathways associated with the aforementioned culture 
system, down regulated pathways were predominantly associated with the TGF-β and Wnt, and 
upregulated pathways associated with CREB. Interestingly, upregulated genes include EP300 and 
CREB Binding Protein (CREBBP). EP300 is a histone acetyltransferase and coactivator and plays a 
vital role in physiological processes including the regulation of embryonic stem cell self-renewal and 
pluripotency (49). The homologous genes CREBBP and EP300 are recruited by Nanog (an identified 
hub gene) through a physical interaction to the Nanog binding loci and play a pivotal role in maintaining 
a proliferative and undifferentiated population of stromal stem cells (50). Additionally, CREB-mediated 
signalling has been implicated in the expansion and self-renewal of muscle stem cells to preserve stem 
cell function (51). Interestingly, CREB has also been linked with in vivo bone formation, with prolonged 
activation of the cAMP pathway by either dibutryl-cAMP (52) or forskolin (53) shown to stimulate in 
vitro and in vivo bone formation from human MSCs.  Furthermore, CREB is linked to periosteal 
biology. Indeed, PDGF secreted by TRAP+ mononuclear cells have been shown to maintain the 
periosteum microenvironment potentially though its induction of pCREB binding to the periostin 
promoter (54).  
 
As previously mentioned, an overall decrease in WNT signalling was apparent in cells cultured in the 
PD-GFC relative to FBS. With reference to the initial take-one-away study, the presence of WNT3a 
had a negative effect on cell proliferation and as such was eliminated from further analysis. 
Interestingly, the six growth factors selected in addition to the 3D matrix induced an autonomous 
downregulation of WNT signalling, further highlighting the need to eliminate this pathway. Indeed, it 
is known that activation of WNT signalling leads to periosteal bone formation, presumably as a direct 
result of periosteal stem cell differentiation (55). TGF- signalling was also down-regulated in this 
system. Specifically, the type 1 receptor ACVR1B and the type 2 receptor ACVR2B was 
downregulated. These two receptors form the signalling complex for activins including Activin a, 
Activin b and Nodal. This signalling pathway functions through the interaction of Smad2/3 with Smad4, 
which is also downregulated in our analysis. Interestingly, Activin/Nodal signalling has been implicated 
in both pluripotent and adult stem cell fate choices (56). 
 
Overall, the PD-GFC developed in the current study represents a defined media for the expansion of 
hPDCs in vitro, whilst retaining cell identity and improving potency. Incorporating PD-GFC cultured 
cells in a collagen type-1 matrix mimicked native periosteum through cell localisation. Regulation of 
specific pathways in response to PD-GFC and the environment suggest the enrichment or modification 
of hPDCs to mimic the periosteal progenitor niche. These data could provide the basis for an ‘off the 
shelf’ periosteum mimetic to replace periosteal grafting in vivo, however, efficacy of such a construct 
would firstly need to be tested preclinically. 
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Supplementary Figure 1: Validation of RNA Sequencing 
Validation of RNA Seq data was performed on RNA obtained from the hPDCs cultured in 10% hAS or 
FBS using qPCR. The selected genes were based on RNA Seq fold changes (highly up or down regulated 
(fold change >20), moderate regulation (fold change of 10-20) and low up and down regulated (fold 
change >20)) in cells cultured in hAS (n=3) compared to FBS (n=3). Data are presented as the ratio of 
cells cultured in 10% FBS/ 10% hAS.  Minimal fold change differences in gene expression were 






















































































Supplementary Figure 2: hPDC morphology following removal of IGF-1 and PDGF-BB 
Light microscopic images of hPDCs cultured the absence of IGF-1 and PDGF-BB showing an induction 
of a heterogeneous culture and or stress fibers compared to all factor or FBS culture (indicated by 



























S u p pl e m e nt a r y Fi g u r e 3: C ell d e nsit y m o d ul at es mi g r ati o n of h P D Cs  t o t h e F L S wit h 1 0 0, 0 0 0 
c ell s r e pli c ati n g as p e ct s of p e ri ost e al bi ol o g y.  ( A) Hist ol o gi c al ( H & E) i m a g es of h P D Cs c ult ur e d i n 
F B S or P D -G F C f or 7 or 1 4 d a ys at eit h er 3 0, 0 0 0 or 1 0 0, 0 0 c ell s p er g el ( 2 1. 7 6 m m 3 ).  N ot e c ell 
or g a ni z ati o n al o n g o n e s urf a c e at t h e 1 0 0, 0 0 0-c ell d e nsit y, c ult ur e d i n P D -G F C at D a y 1 4  ( S c al e b ar: 
5 0  m).  ( B) G e n e e x pr es si o n of k e y g e n es as s o ci at e d wit h p eri ost e al bi ol o g y i n c ell s c ult ur e d i n 
st a n d ar d vs b i o mi m eti c ( 1 0 0, 0 0 0-c ell d e nsit y, c ult ur e d i n P D -G F C at D a y 1 4 i n pl asti c -c o m pr e ss e d 
g el s; D at a ar e pr es e nt e d as t h e m e a n ± S. E. M, St ati sti c al a n al ysis p erf or m e d usi n g o n e -w a y A N O V A, 
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Primer sequences for RT-PCR. Primers used for validation of  
RNA SEQ data. 




Supplemetary Table 2 
 









Triamcinolone Acetonide 4.26E-11 












List of upstream transcriptional regulators identified using IPA. They are listed in order of their p-value of 




















Supplementary Table 3 
Network Hub Genes 
1) Cancer, Organismal Injury and 
Abnormalities, Gastrointestinal Disease 
Akt, MYOC, Integrin, TRIB3 
2) Cancer, Gastrointestinal Disease, 
Organismal Injury and Abnormalities 
ERK, FGFR2, Rb, FGF9, HDAC, Cyclin E, 
Cyclin A, E2f 
3) Cellular Movement, Hematological System 
Development and Function,  
     Hypersensitivity Response  
VCAM1, Rac, GSK3, LEF1, p85 
4) Embryonic Development, Organismal 
Development, Tissue Development 
IGF1, MApk, IGF2, VEGF, CDH1, MAPK1/2, 
TNFRS11B 
5) Cellular Movement, Hematological System 
Development and Function,  
     Immune Cell Trafficking  
ERK 1/2, CTGF, MMP1, COll4, IL-17R, 
GREM1 
6) Cellular Development, Cellular Growth 
and Proliferation, Hematological System         
Development and Function 
NF-kB, Nfat, IgE, TNFSF4 
7) Dermatological Diseases and Conditions, 
Organismal Injury and Abnormalities, 
Skeletal and Muscular System Development 
and Function 
PDGF, PKc, TNF family, Pld, hsp27 
8) Cancer, Organismal Injury and 
Abnormalities, Reproductive System Disease 
RhoA, Tp53, NR3C1 
9) Hereditary Disorder, Metabolic Disease, 
Organismal Injury and Abnormalities  
 
EGFR, Cul3 
10) Neurological Disease, Skeletal and 
Muscular Disorders, Psychological Disorders  
 
Ras homolog, PLC, Ras, Adcy, p38 MAPK, 
NMDA 
 
Hub genes identified in each of the top 10 networks generated by IPA. Each network is associated 


























Target Molecules Main 
Networks 
Involved  























➢ Recent studies have shown that 17-estradiol can effectively 
improve bone marrow- mesenchymal stem cell- (BM-MSC) 
proliferation in mice and rats (57)(33).  
➢ Estrogen has been confirmed to enhance the differentiation 
potential of hMSCs and to up-regulate their telomerase activity as 
a means of preventing telomere shortening via ER, thus, 
inhibiting senescence of MSC. Upon estrogen supplementation, 
hMSCs demonstrated a significant increase in their proliferative 
rate; the cells maintained the differentiation potential at 
concentrations ranging from 10-9 and 10-8 M (33)(58).  
➢ 17-estradiol can regulate and significantly improve MSC 
proliferation in vitro, effectively improving MSC numbers and 
differentiation capacity required for stem cell-based tissue 
engineering. However, (33), male and female donor MSC 
proliferation differs in the presence of 17-estradiol.  
➢ The above claims can be further confirmed by Chen, et al stating 
estrogens functional involvement in enhancing the osteogenic 
activity of MSCs and their differentiation into osteoblasts. This 
was established by an increase in osteocalcin and ALP expression 
in estrogen treated MSCs (59). 
Dexamethaso
ne 















➢ Dexamethasone (Dex) is known to be able to exert multiple effects 
on the same cell population according to the concentration of Dex 
present around and within the cells system. hBM-MSCs cultured 
in a Dex concentration of 10-8 M has shown to negatively regulate 
the transcription of genes associated with apoptosis and 
differentiation, while genes implicated in cell proliferation were 
positively regulated by Dex.  
➢ Dex improves the quality of hBM-MSCs as it delays senescence 
and maintains its differentiation potential (35).  
➢ High concentrations of dex (10-6-10-7 M) suppresses the 
proliferation of hMSC-like cells but not their differentiation. Other 
studies however, have shown that this concentration suppresses 
osteogenic differentiation, directing the cells towards an 
adipogenic lineage (60)(61).  
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➢ A study carried out by (62) has shown that MSCs cultured in low 
doses of Dex during the expansion phase, maintain a higher 
proliferative potential then cells cultured in the absence of Dex 
over repeated passages. Cells become phenotypically stable upon 
passaging.  
➢ Dex can also initiate osteogenesis via Wnt/ -catenin canonical 
pathway and an alternative pathway- the MAPK phosphatase 
(MKP-1) causing the expression of osteocalcin, BSP and RUNX2 
(63). 
➢ Overall, Dex can induce either differentiation or proliferation in a 

















➢ Kwon, Y. W., et al (2013) investigated the expression of pro-
angiogenic factors IL-6 and IL-8 on TNF stimulated hMSCs 
(64). At a concentration of 10 ng/ml, TNf cultured cells 
stimulated angiogenesis and tissue repair (in 48hrs) (64).  
➢ Furthermore, hMSC were subjected to a range of TNF 
concentrations, from 0.5-50 ng/mL, in a study carried out by 
Croes, M. et al (2015). Lower concentrations of 5 ng/mL 
demonstrated higher ALP activity compared to control, and 
highest calcium deposition, both at a concentration of 5 ng/mL 
(40).  
➢ An additional study investigated the long term incubation of 
hMSCs with TNF in the induction of a neural phenotype (65). 
The Cells were subjected to TNF stimulation with either a 
concentration of 5 ng/mL or 50 ng/mL. The lower dose of the 
cytokine exhibited a stimulatory effect on cell division with a 2-
fold increase. Overall, these findings indicate the need to utilise a 
low concentration of TNF (65).  









➢ hMSCs cultured in a 3D polyethylene glycol (PEG) hydrogel in 
the presence of PDGF-BB were able to induce the activation of 
hMSCs, induce proliferation, spreading and migration (37). 
➢ PDGF is known to synergistically enhance osteogenic 
differentiation through crosstalk between MEK- and PI3K/Akt-
mediated signalling (66). PDGF alone, however, showed no 
signs of osteogenic differentiation in hMSCs (66).  








➢ Wnt3a signals through the Wnt/ -catenin canonical pathway in 
regard to its importance in bone formation involving MSCs.  
➢ Wnt3a-associated responsive promoter activation as a result of 
the Wnt signalling activation, depends on the MSC 
differentiation state. Wnt3a exposure has shown to inhibit MSC 
osteogenic differentiation, further decreasing matrix 
mineralisation and ALP activity (67). 
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➢ Its overall effect drives an increase in cell number resulting 
from an enhanced proliferative activity and a decrease in 
apoptosis, particularly during the expansion of undifferentiated 
MSCs (68). 
➢ Another study demonstrated the proliferative ability of Wnt3a 
on hMSCs while retaining pluripotency (36).  
➢ Boland et al. have also shown that when osteogenically 
differentiated MSCs are treated with Wnt3a, it results in a 
decrease in osteoblastic marker gene expression. Canonical Wnt 
signalling functions in maintaining an undifferentiated, 
proliferating progenitor MSC population, whereas non-
canonical Wnt signalling drive osteogenic differentiation via 
Wnt5a (68). To date, contradicting effects of Wnt3a are 
observed on MSC differentiation.   
 









➢ VEGF belongs to the PDGF superfamily and is known to play 
a significant role in regulating angiogenesis and driving 
osteogenesis in bone repair and remodelling.  
➢ VEGF has demonstrated its role in regulating hMSC 
differentiation potential. It controls the balance between 
osteogenesis in BM-MSCs via an intracrine mechanism but 
stimulates osteoclastogenesis and adipogenesis in a paracrine 
mechanism (69)(70).  
➢ In conjunction with its effects on stem cell fate, VEGF has been 
shown to increase MSC proliferation significantly in a study 
carried out by (38).  
➢ Profiled but not constant dose of VEGF had a significant impact 
on cell numbers. In comparison to the other growth factors 
tested as well in this study (IGF-1, FGF-2, BMP-2), VEGF 
demonstrated the highest proliferative rate in MSCs (38).  
➢ According to this study, VEGF did not impact the 
differentiation potential and mineralization of MSCs. This is in 
agreement with a previous study confirming an increase in 
VEGF in the early proliferation stage of MSC during bone 
repair (38).  
➢ The effects of 17-estradiol on hMSC proliferation have shown 
to coincide with an increase in VEGF, both enhancing the cells 
proliferative potential (58).  
➢ Furthermore, a separate study has demonstrated an inhibitory 
effect of VEGF on osteogenic commitment via the down 
regulation of BMP2 in rat MSCs, additionally attenuating 
MSCs differentiation potential (71). 
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➢ As demonstrated by (72), TGF- 1 induces the translocation of 
-catenin in MSCs in smad3- dependent manner, further 
inhibiting adipogenic differentiation (41). This pathway 
promotes the stimulation of MSC proliferation (41) and 
subsequently driving the inhibition of MSC osteogenic 
differentiation. 
➢ A more recent study carried out by Yakota et al. have published 
findings supporting TGF’s importance in regulating 
osteogenic differentiation. 
➢ TGF plays a significant role in maintaining osteoblastic 
differentiation and proliferation, although inhibiting their 
maturation and mineralisation. This is induced via the activation 
of downstream intracellular effector molecules such as MAPKs 
(ERK pathway, p38 and JNK) and Smads (66). 






5 ➢ According to Ahn et al. hMSCs cultured in the presence of 
FGF2 demonstrated enhanced growth and further maintained 
the cells pluripotent state during expansion. The associated 
MAPK signalling cascade, mediated by ERK, JNK and p38 
protein kinase, primarily drives the cell’s proliferative ability. 
➢ In accordance to the study carried out by (39), JNK was found 
to play a major role in the FGF2-induced responses in regards 
to increasing the proliferation rate and survival of hMSCs but 
reducing their differentiation potential (39)(73). 







4 ➢ IGF-1 plays a critical role in bone formation and remodelling 
(42)(38). As confirmed by a number of studies, neutralising 
IGF-1 has shown to decrease ALP-2 activity and osteocalcin 
release from MSCs. Thus, demonstrating the essential role of 
IGF-1 in osteogenesis.  
➢ On the contrary, Huang et al. have demonstrated the inhibitory 
effect of exogenous IGF-1 on MSC osteogenic differentiation. 
(38). 
➢ Doorn et al investigated the effects of IGF-1 on hMSC 
proliferation and differentiation, confirming a concentration of 
20 ng/mL demonstrating MSC proliferation. This study 
demonstrated the role of IGF-1 in inducing proliferation, 
expression of ALP and osteogenic gene expression of hMSC 
with a minimal effect of bone formation in vivo (74).  
➢ These findings confirm the role IGF-1 in both bone formation 
and resorption. 
 
Factors selected for the development of hPDC specific media. All 9 factors were shown to be primary hub genes in the study. P value of overlap determines whether there is a 
significant overlap between RNA Seq gene data set and the genes regulated by a specific upstream regulator (predicted regulated gene sets generated by IPA). The more 
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significant the overlap of an upstream regulator, the more the overlap of its target molecules that are expressed in the gene data set and predicted by IPA. The networks involved 
refer to the gene networks generated by IPA of which these selected factors are in association with.  Please note: the ‘Evidence to support selection of upstream regulators’ is 













Density at Harvest 
(cells/cm2) 
(mean  S.E.M) 
Population 
Doublings 




(mean  S.E.M) 
1% FBS 4,000 12,089  1,060 1.57  0.20 12.48  1.4 
10% FBS 4,000 22,444  1,756* 2.48  0.07*** 2.02  0.06*** 
PD-GFC 4,000 27,222  2,946*** 2.75  0.17*** 2.20  0.14*** 
 
 
Data associated with a typical passage in each of the media formulations investigated in this study. (Data are presented as the mean ± S.E.M, 
Statistical analysis performed on all conditions relative to 1% FBS using one-way ANOVA, uncorrected Fischer’s LSD; ***p<0.001; *p<0.05; 
n=3). 
 
 
 
 
 
 
 
 
 
